HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 37, 28341-28344, September 15, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/37/28341    most recent C000352200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hahn, H. Articles by Zimmer, A. Search for Related Content PubMed PubMed Citation Articles by Hahn, H. Articles by Zimmer, A. Social Bookmarking                      What's this?

ACCELERATED PUBLICATION
Patched Target Igf2 Is Indispensable for the Formation of Medulloblastoma and Rhabdomyosarcoma^*

Heidi Hahn^§, Leszek Wojnowski^¶, Katja Specht, Roland Kappler, Julia Calzada-Wack, Diana Potter, Anne Zimmer^¶**, Ulrike Müller, Elenore Samson, Leticia Quintanilla-Martinez, and Andreas Zimmer^¶**

From the  Institute of Pathology, TUM Technical University of Munich/GSF Research Center of Environment and Health, Ingolstädter Landstrasse 1, 85758 Neuherberg, Federal Republic of Germany, the ^¶ Laboratory of Genetics, NIMH, National Institutes of Health, Bethesda, Maryland 20892, the  Veterinary Medicine and Resources Branch, NIMH, National Institutes of Health, Bethesda, Maryland 20892, the ^** Clinic for Psychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Federal Republic of Germany

Received for publication, May 31, 2000, and in revised form, June 16, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children (Dagher, R., and Helman, L. (1999) Oncologist 4, 34-44), whereas medulloblastoma, a highly malignant tumor of the cerebellum, accounts for 20% of childhood brain tumors (Goodrich, L. V., and Scott, M. P. (1998) Neuron 21, 1243-1257). Both tumors are associated with a deficiency in the tumor suppressor Patched (PTCH) in Gorlin syndrome (Gorlin, R. J. (1987) Medicine (Baltimore) 66, 98-113), and they are present in the corresponding murine models. RMS in Ptch mutant mice consistently contain elevated levels of the tumor growth-promoting insulin-like growth factor 2 (Igf2). We have investigated the mechanism of Igf2 overexpression and its significance in medulloblastoma and RMS tumorigenesis. Here we report that Igf2 is indispensable for the formation of medulloblastoma and RMS in Ptch mutants. Overexpression of Igf2 in RMS in these mice does not involve loss of imprinting, uniparental disomy, amplification of the Igf2 locus, or polyploidy. Since Igf2 is also overexpressed in non-tumor tissue deficient in Ptch, these observations suggest that Ptch regulates Igf2 levels through a transcriptional mechanism. They also identify Igf2 as a potential target for medulloblastoma and RMS.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Somatic or inherited deficiency in the tumor suppressor PTCH leads to the formation of several tumor in man, including basal cell carcinoma, fibroma, medulloblastoma, and RMS¹ (6). Medulloblastoma and RMS are childhood tumors with dismal prognosis (7). Protein sequence analysis indicated that PTCH is a plasma membrane protein with 12 transmembrane domains (8-10). Recent studies have identified two proteins that directly interact with PTCH. The morphogene Sonic Hedgehog (11) binds PTCH, this is thought to activate a second protein interacting with PTCH, the seven-transmembrane domain protein Smoothened (12). Activation of Smoothened leads to the overexpression of the proto-oncogene Gli1 and of some members of the Wnt and TGF- gene families (13). Many aspects of PTCH signaling remain obscure and PTCH may have additional roles that are independent from these partners (6).

We and others have recently established Ptch-deficient mouse strains that exhibit a high incidence of medulloblastoma (4, 5) and RMS (5). The latter, more accessible tumor consistently overexpresses Igf2 (5), an important modulator of muscle growth and differentiation as well as a mitogen for many cell types (14). In most tissues, both in humans and in mice, the gene is imprinted with only the paternally derived allele being transcribed (15). Overexpression of Igf2 has been observed in several types of sporadic human neoplasms and this has been frequently attributed to loss of imprinting (LOI) of the maternal allele (16, 17). Consequently, LOI of Igf2 has been proposed as an important mechanism of tumor formation (18). Overexpression of Igf2 could also be caused by uniparental disomy involving duplication of the paternal (non-imprinted), and loss of the maternal (imprinted), locus (16). Alternatively, increased Igf2 transcription could reflect an amplification of the Igf2 gene in the tumor or Igf2 being the target of an abnormally activated signaling pathway.

We have investigated the significance of Igf2 and the mechanism of Igf2 overexpression in tumor formation in Ptch mouse mutants. In this communication we show that Igf2 is indispensable for the formation of both RMS and medulloblastoma. We propose that Igf2 acts as a downstream target of the Ptch-signaling pathway (19) and as such represents a target for therapies against malignancies caused by loss of Ptch function.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Mouse Breedings and Crosses

Ptch^neo67/+/Igf2^+/ Double Mutants-- Wild-type Ptch^+/+ and heterozygous Ptch^neo67/+ mice on an Igf2-deficient background were obtained by crossing heterozygous Ptch^neo67/+ females (maintained on a CD1 background) with heterozygous Igf2^+/ males (20), kindly provided by Dr. A. Efstratiadis, Columbia University, New York). The colony was monitored for tumor formation over a period of 9 months.

(CDI (Ptch^neo67/+) × CAST/E_i) F1 Cross-- Mus musculus castaneus males were mated to Ptch^neo67/+ females maintained on a CD1 background. The resulting offsprings of CDI (Ptch^neo67/+) × CAST/E_i) F1 generation were monitored for tumor formation. The imprinting status of Igf2 and H19 in normal skeletal muscle (SM) and RMS was then investigated by SNuPE (single nucleotide primer extension) assay (see below).

(CDI (Ptch^neo67/+) × CAST/E_i) F1 × CDI (Ptch^neo67/+) Backcross-- To investigate the imprinting status of Igf2 and H19 in E8.5 Ptch^+/+, Ptch^neo67/+, and Ptch^neo67/neo67 embryos, Ptch^neo67/+ females derived from the (CDI (Ptch^neo67/+) × CAST/E_i) cross were mated to CDI (Ptch^neo67/+) males. Embryos that inherited both the M. musculus domesticus and M. musculus castaneus Igf2 alleles were identified by sequencing and pooled according to the Ptch genotype (Ptch^+/+, Ptch^neo67/+, and Ptch^neo67/neo67). Considering the small physical distance of 90 kilobases (21) between Igf2 and H19 genes on murine chromosome 7, the sequencing of the Igf2 polymorphism was used to determine the origin of both Igf2 and H19 alleles.

Genotyping of Ptch and Igf2 Mutant Alleles

Genotyping of mice and embryos was performed by PCR on DNA isolated from tail clips or yolksacs, respectively. The genotyping of the wild-type and Ptch^neo67/+ mutant loci was described previously (5). The genotyping of the mutant Igf2 allele was performed using the following oligonucleotides: neo3, 5'-AGCGCATCGCCTTCTATCGCCTTCTT-3' (derived from the neo cassette of the Igf2 targeting construct) and Igf2wtR, 5'-CCTTCCCCAACTGGGAAATCAAGAGA-3' (derived from intron 4 of the murine Igf2 gene; GenBank^TM accession number U71085, nucleotides 23080-23105). The oligonucleotides amplify a ~350-base pair fragment of the mutant Igf2 allele. The PCR conditions were 35 cycles of denaturing for 45 s at 95 °C, annealing for 90 s at 55 °C, and extension for 45 s at 72 °C.

Northern Blot

E8.5 Ptch^+/+, Ptch^neo67/+, and Ptch^neo67/neo67 embryos from crosses between Ptch^neo67/+ mice (CD1 background) were isolated and genotyped. Embryos of the same genotype were pooled and total RNA was isolated using a single step acid guanidinium thiocyanate-phenol-chloroform procedure (22). Hybridizations were performed in formamide-containing solutions. The amount of total RNA (15 µg/lane) was monitored by ethidium bromide staining and by hybridization with a murine Actin probe. The same protocol was used to investigate RNA isolated from SM and RMS of heterozygous Ptch animals. The Igf2 and Gli1 probes were described previously (5). The H19 probe corresponds to exon 5 of the murine H19 gene.

Quantitative Genomic and RT-PCR

Quantitative real-time PCR was carried out using a TaqMan (Applied Biosystems 7700) instrument. The murine Igf2-specific primers were 5'-TGTGCTGCATCGCTGCTTAC-3' and 5'-CGGTCCGAACAGACAAACTGA-3', and the fluorogenic probe was 5'-CCCGGAGAGACTCTGTGCGGAGG-3'. Amplification of mGAPDH as an endogenous control was performed to standardize the amount of sample RNA or DNA. The mGAPDH primers were 5'-TCCATGCCATCACTGCCA-3' and 5'-GATGCAGGGATGATGTTCTGG-3', and the fluorogenic probe was 5'-CAGAAGACTGTGGATGGCCCCTC-3'. PCR was carried out with the TaqMan Universal PCR Master Mix (Applied Biosystems) using 50 ng of cDNA or 50 ng of genomic DNA, 200 nM amount of the probe and 300 nM forward primer and reverse primer in a 30-µl final reaction mixture. After 2-min incubation at 50 °C to allow for uracil-N-glycosylase cleavage to hydrolyze uracil-glycosidic bonds at dU-containing DNA sites, AmpliTaq Gold was activated by incubation for 10 min at 95 °C. Each of the 50 PCR cycles consisted of 15 s denaturation at 95 °C and hybridization of probe and primers for 1 min at 60 °C. All data shown are the average of at least two independent experiments.

SNuPE Assay

SNuPE assay (23) was used to assess the imprinting status of Igf2 and H19 as well as to exclude the uniparental disomy of chromosome 7. The assay is based on exon sequence differences between M. musculus domesticus and M. musculus castaneus. To assess the imprinting status of Igf2 and H19 in SM, RMS, and in E8.5 Ptch^+/+, Ptch^neo67/+, and Ptch^neo67/neo67 embryos, total RNA was isolated and digested with DNase. Two µg RNA were reverse-transcribed using random hexamers and Superscript II (Life Technologies, Inc.). The Igf2 and H19 cDNAs were amplified by PCR. The oligonucleotides used were derived from neighboring exons to allow the detection of contamination by genomic DNA (23). Although none of the RT-PCR samples had a detectable contamination with genomic DNA, the PCR fragments were gel-purified prior to the SNuPE assay.

The 10 µl SNuPE reaction mix contained 1× PCR buffer (Amersham Pharmacia Biotech, 1.5 mM MgCl₂), 10 ng of the amplified cDNA fragment, 10 µmol of the respective SNuPE primer, 1 unit of Taq DNA polymerase, and 2 µCi of the appropriate [-³²P]dNTP (23). After denaturing at 95 °C for 5 min, the annealing of the oligonucleotide was performed at 55 °C for 75 s and the oligonucleotide extension at 72 °C for 1 min. The samples were diluted in 30 µl of stop solution (10 mM NaOH, 95% formamide, 0.1% bromphenol blue, and 0.01% xylene cyanol). After boiling, 2.5 µl were resolved by electrophoresis on a renaturing 10% polyacrylamide gel, blotted onto Whatman paper, and visualized by autoradiography. Experiments designed to exclude the uniparental disomy of chromosome 7 differed from the above by the omission of the reverse transcription step and usage of genomic DNA instead of cDNA.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

We investigated the significance of Igf2 and the mechanism of its overexpression in tumor formation in heterozygous Ptch^neo67/+ mice. To this end, the Ptch mutation was transferred onto an Igf2-deficient background (24) by mating of heterozygous Ptch^neo67/+ females with heterozygous Igf2^+/ males. Offspring animals with a paternally inherited Igf2 mutant allele lack Igf2 expression due to the imprinting of the maternal Igf2 allele (20). In agreement with previous studies (5, 24), we observed a relative loss of Igf2 and Ptch mutant mice upon weaning (Table I). All surviving animals were monitored for tumor formation over a period of 9 months. Heterozygous Ptch^neo67/+ mice are mainly predisposed to medulloblastoma and RMS (4, 5). Over a period of 9 months, seven heterozygous Ptch^neo67/+ animals developed RMS, whereas five developed medulloblastoma manifesting as hydrocephalus. Three Ptch^neo67/+ heterozygotes animals died of unknown causes (Table I). Strikingly, tumor formation and animal loss were confined to animals wild-type for Igf2 (Ptch^neo67/+/Igf2^+/+), whereas no tumors were found in animals with inherited mutant Igf2 allele (Ptch^neo67/+/Igf2^+/) (Table I). These results suggest that Igf2 is required for the formation of RMS and medulloblastoma caused by loss of Ptch function.

View this table: [in this window] [in a new window]   Table I Tumor formation and animal loss in Ptch and Igf2 mutant mice A colony of 154 mice derived from a cross between Ptch neo67/+ females and Igf2+/ males was monitored for tumor formation over a period of 9 months. Only mice with a Ptchneo67/+Igf2+/+ genotype developed tumors.

Because Igf2 is overexpressed in RMS (5) and is indispensable for tumor formation, we wished to determine the mechanism involved in Igf2 overexpression. Igf2 transcripts were quantitated using a TaqMan assay. As shown in Fig. 1a, RMS in Ptch mutant mice show an up to 1000-fold increase of Igf2 transcription in comparison with normal SM. To assess the imprinting status of Igf2 alleles we introduced into the colony a M. musculus castaneus-specific Igf2 polymorphism (23) by mating M. musculus castaneus males with M. musculus domesticus females heterozygous for Ptch in a CDI(Ptch^neo67/+) × CAST/E_I cross. The allelic origins of Igf2 transcripts in the offspring of this cross were investigated using a SNuPE assay (23). RMS expressed Igf2 only from the paternally inherited Igf2 allele (Fig. 1b). These results argue against an abnormal Igf2 imprinting in RMS. Unexpectedly (20), we also found a weak level of expression of the maternal Igf2 allele in the normal adult muscle (Fig. 1b).

View larger version (42K): [in this window] [in a new window]   Fig. 1.   Igf2 and H19 expression in Ptchneo67/+ heterozygous mice. a, quantitative TaqMan analysis of Igf2 expression in normal muscle (SM) and in RMS of seven different Ptchneo67/+ heterozygous mice (M1-M7). b, SNuPE analysis of Igf2 in RNA (left panel) and genomic DNA (right panel) from SM (1-5) and RMS (1T-5T) isolated from the offspring of the CDI (Ptchneo67/+) × CAST/Ei cross. The specifity of the SNuPE assay (middle panel) was confirmed using genomic DNA of wild-type M. musculus domesticus (a), M. musculus castaneus (b), and a M. musculus domesticus/M. musculus castaneus cross (a/b). c, overexpression of H19 transcripts in RMS in comparison with SM from Ptchneo67/+ heterozygotes (CDI background) in Northern blot analysis. d, allele-specific expression of H19 assessed by SNuPE assay in SM (1-5) and RMS (1T-5T) derived from 5 Ptchneo67/+ heterozygotes of the (CDI (Ptchneo67/+) × CAST/Ei) cross.

Next, we investigated the imprinting status of the physically linked, paternally imprinted gene H19. H19 and Igf2 expression are functionally linked due to the competition for a common enhancer (25). Reduction or loss of H19 expression would therefore be expected to result in an increase in Igf2 transcription on the same chromosome. As shown in Fig. 1c, H19 itself is overexpressed in RMS of heterozygous Ptch^neo67/+ mice. A SNuPE assay that detects an H19 polymorphism between M. musculus domesticus and M. musculus castaneus (23) showed a normal imprinting of H19 in normal and tumorigenic muscle tissue of (CDI (Ptch^neo67/+) × CAST/E_i) mice (Fig. 1d). All these results argue against an abnormal imprinting as a source of Igf2 overexpression.

Other possible mechanisms of Igf2 overexpression are uniparental disomy, amplification of the Igf2 gene, or polyploidy. Uniparental disomy is caused by a loss of the maternal (imprinted) Igf2 locus with a concomitant duplication of the paternal (not imprinted) Igf2 locus (16, 26). However, both the M. musculus domesticus and M. musculus castaneus Igf2 alleles can be detected in genomic DNA isolated from RMS and analyzed by SNuPE assay (Fig. 1b) and sequencing (not shown). Gene amplification and polyploidy in RMS have been similarly excluded by quantitative PCR (TaqMan) (Fig. 2) and flow cytometry (not shown), respectively.

View larger version (23K): [in this window] [in a new window]   Fig. 2.   Quantification of Igf2 DNA in normal muscle (SM) and RMS of 7 Ptchneo67/+ heterozygotes mice (M1-M7) using TaqMan.

These results indicated that Igf2 overexpression in RMS is caused exclusively by an increased transcription of the paternal allele. They also suggest the involvement of a signaling rather than a genetic mechanism. If Igf2 were a target of activated Ptch signaling, its overexpression should be detectable in tissue from a non-tumor bearing, Ptch-deficient animal. We therefore examined Igf2 expression in E8.5 Ptch^+/+, Ptch^neo67/+, and Ptch^neo67/neo67 embryos derived from crosses between Ptch^neo67/+ mice. In the embryo proper, Igf2 expression is detectable for the first time at E7.5 in embryonic mesoderm, and at E8.5 Igf2 is expressed in many embryonal tissues (27). As shown in Fig. 3a, gradual loss of the Ptch wild-type alleles correlated with an increase in Igf2 expression in E8.5 embryos. A similar relationship has been found for H19 (Fig. 3b). The increase in the expression of these genes following the loss of Ptch resembles that of the established Ptch target (4), Gli1 (Fig. 3c).

View larger version (36K): [in this window] [in a new window]   Fig. 3.   Expression of Igf2, H19, and Gli1 in Ptch+/+ (lane 1), Ptchneo67/+ (lane 2), and Ptchneo67/neo67 (lane 3) embryos. a-c, Northern blot analysis. d-e, SNuPE assays for Igf2 and H19 in Ptch+/+, Ptchneo67/+, and Ptchneo67/neo67 embryos derived from a (CDI (Ptchneo67/+) × CAST/Ei) F1 × CDI (Ptchneo67/+) backcross. Genomic Igf2 DNA from M. musculus domesticus (k1) and a M. musculus domesticus × M. musculus castaneus cross (k2) were used as controls for the specifity of the assay.

The allelic source of Igf2 and H19 overexpression in E8.5 Ptch^neo67/+ and Ptch^neo67/neo67 mutant embryos was investigated using the appropriate SNuPE assays on embryos derived from a (CDI (Ptch^neo67/+) × CAST/E_i) F1 × CDI (Ptch^neo67/+) backcross. Only paternally derived Igf2 transcripts (Fig. 3d) were detected in the embryos. The apparent weak expression of the paternal H19 allele (Fig. 3e) may reflect incomplete imprinting or a contamination with mRNA derived from the yolksac (28). These results show that, similarly to the tumor tissue, Ptch-deficient embryos overexpress Igf2 and H19 and that the process does not involve LOI.

Deficiency in the tumor suppressor PTCH has been implicated in a variety of tumors, but the underlying mechanisms remain poorly understood. Several targets of PTCH signaling have been proposed based on their altered expression in tumors resulting from PTCH deficiency. We have investigated the mechanism and the functional significance of the Igf2 overexpression, which is a consistent characteristic of RMS in murine Ptch mutants. Overexpression of Igf2 has been reported in several tumors including RMS and the involvement of abnormal imprinting or genomic instability have been discussed as the underlying mechanism (16). Unexpectedly, we have not detected any evidence for the transcription of the maternal Igf2 gene copy in RMS. Neither have we found evidence for the involvement of genomic instability as judged by the absence of uniparental disomy, amplification of the Igf2 locus, or polyploidy. These observations argue against LOI or genomic instability as a source of Igf2 overexpression. Rather, similarly to Gli1 and Ptch itself (29), Igf2 appears to be a downstream target of an activated Ptch signaling pathway. This conclusion is based on the observation of increased Igf2 expression in non-tumor (embryonic) tissue deficient in Ptch.

Abrogation of Igf2 has been previously associated with a reduction in tumor malignancy in a pancreatic endocrine cancer model (30). Igf2 has also recently been shown to act as a modifier of adenomatous polyposis-related colorectal tumor progression (31). In Ptch mutants, Igf2 appears indispensable for tumorigenesis, since no medulloblastoma or RMS are observed in animals deficient in the gene's product. The suggested functional link between Igf2 and Ptch indicates that prevention of Igf2 overexpression should be attainable by the restoration of Ptch function in the tumor. The absolute dependence of RMS and medulloblastoma formation on Igf2 described here suggests that Igf2 inhibitors may be useful in the treatment of these malignant tumors.

	ACKNOWLEDGEMENTS

We are grateful to Hannelore Prechtl, Jaqueline Müller, and Anna Nickl for excellent animal care and technical assistance. We thank Dr. A. Efstratiadis, Columbia University, New York, for kindly providing heterozygous Igf2^+/ mice.

	FOOTNOTES

^* This work was supported by a BioFuture-Grant of the German Bildung, Wissenschaft, Forschung und Technologie-Ministry for Education and Research (to R. K., J. C.-W., and H. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence should be addressed. Tel.: 49-89-3187-2313 or -2312; Fax: 49-89-3187-3360; E-mail: heidi.hahn@gsf.de.

Published, JBC Papers in Press, July 6, 2000, DOI 10.1074/jbc.C000352200

	ABBREVIATIONS

The abbreviations used are: RMS, rhabdomyosarcoma; LOI, loss of imprinting; SM, skeletal muscle; SNuPE, single nucleotide primer extension; RT-PCR, reverse transcription-polymerase chain reaction.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. R. Parathath, L. A. Mainwaring, A. Fernandez-L, D. O. Campbell, and A. M. Kenney Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors Development, October 1, 2008; 135(19): 3291 - 3300. [Abstract] [Full Text] [PDF]

				R. T. Kurmasheva, J. B. Easton, and P. J. Houghton Combined Targeting of mTOR and the Insulin-like Growth Factor Pathway ASCO Educational Book, January 1, 2008; 2008(1): 460 - 464. [Abstract] [Full Text] [PDF]

				S. Kunder, J. Calzada-Wack, G. Holzlwimmer, J. Muller, C. Kloss, W. Howat, J. Schmidt, H. Hofler, M. Warren, and L. Quintanilla-Martinez A Comprehensive Antibody Panel for Immunohistochemical Analysis of Formalin-Fixed, Paraffin-Embedded Hematopoietic Neoplasms of Mice: Analysis of Mouse Specific and Human Antibodies Cross-Reactive with Murine Tissue Toxicol Pathol, April 1, 2007; 35(3): 366 - 375. [Abstract] [Full Text] [PDF]

				L. Soroceanu, S. Kharbanda, R. Chen, R. H. Soriano, K. Aldape, A. Misra, J. Zha, W. F. Forrest, J. M. Nigro, Z. Modrusan, et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma PNAS, February 27, 2007; 104(9): 3466 - 3471. [Abstract] [Full Text] [PDF]

				S. N. Prince, E. J. Foulstone, O. J. Zaccheo, C. Williams, and A. B. Hassan Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor Mol. Cancer Ther., February 1, 2007; 6(2): 607 - 617. [Abstract] [Full Text] [PDF]

				F. J. Sim, H. M. Keyoung, J. E. Goldman, D. K. Kim, H.-W. Jung, N. S. Roy, and S. A. Goldman Neurocytoma Is a Tumor of Adult Neuronal Progenitor Cells J. Neurosci., November 29, 2006; 26(48): 12544 - 12555. [Abstract] [Full Text] [PDF]

				J. Mao, K. L. Ligon, E. Y. Rakhlin, S. P. Thayer, R. T. Bronson, D. Rowitch, and A. P. McMahon A novel somatic mouse model to survey tumorigenic potential applied to the hedgehog pathway. Cancer Res., October 15, 2006; 66(20): 10171 - 10178. [Abstract] [Full Text] [PDF]

				L. Iacovelli, A. Arcella, G. Battaglia, S. Pazzaglia, E. Aronica, P. Spinsanti, A. Caruso, E. De Smaele, A. Saran, A. Gulino, et al. Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Inhibits the Growth of Medulloblastomas. J. Neurosci., August 9, 2006; 26(32): 8388 - 8397. [Abstract] [Full Text] [PDF]

				N. A. Riobo, K. Lu, X. Ai, G. M. Haines, and C. P. Emerson Jr. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling PNAS, March 21, 2006; 103(12): 4505 - 4510. [Abstract] [Full Text] [PDF]

				S. R. Browd, A. M. Kenney, O. N. Gottfried, J. W. Yoon, D. Walterhouse, C. A. Pedone, and D. W. Fults N-myc Can Substitute for Insulin-Like Growth Factor Signaling in a Mouse Model of Sonic Hedgehog-Induced Medulloblastoma. Cancer Res., March 1, 2006; 66(5): 2666 - 2672. [Abstract] [Full Text] [PDF]

				J. Harper, J. L. Burns, E. J. Foulstone, M. Pignatelli, S. Zaina, and A. B. Hassan Soluble IGF2 Receptor Rescues ApcMin/+ Intestinal Adenoma Progression Induced by Igf2 Loss of Imprinting Cancer Res., February 15, 2006; 66(4): 1940 - 1948. [Abstract] [Full Text] [PDF]

				T. G. Oliver, T. A. Read, J. D. Kessler, A. Mehmeti, J. F. Wells, T. T. T. Huynh, S. M. Lin, and R. J. Wechsler-Reya Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma Development, May 15, 2005; 132(10): 2425 - 2439. [Abstract] [Full Text] [PDF]

				W. Hartmann, A. Koch, H. Brune, A. Waha, U. Schuller, I. Dani, D. Denkhaus, W. Langmann, U. Bode, O. D. Wiestler, et al. Insulin-Like Growth Factor II Is Involved in the Proliferation Control of Medulloblastoma and Its Cerebellar Precursor Cells Am. J. Pathol., April 1, 2005; 166(4): 1153 - 1162. [Abstract] [Full Text] [PDF]

				L. Di Marcotullio, E. Ferretti, E. De Smaele, B. Argenti, C. Mincione, F. Zazzeroni, R. Gallo, L. Masuelli, M. Napolitano, M. Maroder, et al. RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma PNAS, July 20, 2004; 101(29): 10833 - 10838. [Abstract] [Full Text] [PDF]

				P. Levy, I. Bieche, K. Leroy, B. Parfait, J. Wechsler, I. Laurendeau, P. Wolkenstein, M. Vidaud, and D. Vidaud Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Identification of a Gene Expression Signature of Poor Prognosis Clin. Cancer Res., June 1, 2004; 10(11): 3763 - 3771. [Abstract] [Full Text] [PDF]

				A. M. Kenney, H. R. Widlund, and D. H. Rowitch Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors Development, January 1, 2004; 131(1): 217 - 228. [Abstract] [Full Text] [PDF]

				R. J. Wechsler-Reya Analysis of Gene Expression in the Normal and Malignant Cerebellum Recent Prog. Horm. Res., January 1, 2003; 58(1): 227 - 248. [Abstract] [Full Text] [PDF]

				P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al. Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary Clin. Cancer Res., December 1, 2002; 8(12): 3646 - 3657. [Abstract] [Full Text] [PDF]

				H. L. Weiner, R. Bakst, M. S. Hurlbert, J. Ruggiero, E. Ahn, W. S. Lee, D. Stephen, D. Zagzag, A. L. Joyner, and D. H. Turnbull Induction of Medulloblastomas in Mice by Sonic Hedgehog, Independent of Gli1 Cancer Res., November 15, 2002; 62(22): 6385 - 6389. [Abstract] [Full Text] [PDF]

				I. D. Louro, E. C. Bailey, X. Li, L. S. South, P. R. McKie-Bell, B. K. Yoder, C. C. Huang, M. R. Johnson, A. E. Hill, R. L. Johnson, et al. Comparative Gene Expression Profile Analysis of GLI and c-MYC in an Epithelial Model of Malignant Transformation Cancer Res., October 15, 2002; 62(20): 5867 - 5873. [Abstract] [Full Text] [PDF]

				Luis Del Valle, S. Enam, A. Lassak, J. Y. Wang, S. Croul, K. Khalili, and K. Reiss Insulin-like Growth Factor I Receptor Activity in Human Medulloblastomas Clin. Cancer Res., June 1, 2002; 8(6): 1822 - 1830. [Abstract] [Full Text] [PDF]

				Q. R. Lu, J. K. Park, E. Noll, J. A. Chan, J. Alberta, D. Yuk, M. G. Alzamora, D. N. Louis, C. D. Stiles, D. H. Rowitch, et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors PNAS, August 23, 2001; (2001) 181340798. [Abstract] [Full Text] [PDF]

				Q. R. Lu, J. K. Park, E. Noll, J. A. Chan, J. Alberta, D. Yuk, M. G. Alzamora, D. N. Louis, C. D. Stiles, D. H. Rowitch, et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors PNAS, September 11, 2001; 98(19): 10851 - 10856. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 275/37/28341    most recent C000352200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hahn, H. Articles by Zimmer, A.